Site comparison
Amavita Research vs. Headlands Research: which clinical trial site fits your study?
Sponsors comparing Amavita Research with Headlands Research are weighing two Florida-rooted options: an independent cardiovascular specialist in Miami against a growing site network headquartered in West Palm Beach with real cardiometabolic depth. This page compares the models factually.
Amavita Research is a clinical trial site and PET imaging trial partner in North Miami Beach, anchored by a single dedicated cardiovascular site. The senior PI is U.S. TAVR pioneer Dr. William W. O'Neill, National PI on Edwards PARTNER, Protect II, and Protect IV. Every active study is cardiovascular, the affiliated Advanced Cardiovascular of Miami ASC supports interventional procedures on site, and processes are IAOCR GCSA-certified, valid through February 28, 2027.
Headlands Research is a clinical trial site network headquartered in West Palm Beach, Florida, with a stated cardiometabolic emphasis. In June 2026 it acquired Clinical Trials Research in the Sacramento area - two sites with 25 years of cardiometabolic experience and more than 300 completed Phase I-IV trials across hypertension, hyperlipidemia, heart failure prevention, and metabolic disease - and in September 2026 it announced a new de novo site in Grand Rapids, Michigan with cardiometabolic capacity. That is genuine network-level cardiometabolic investment.
The trade-off is concentration versus scale. Headlands distributes cardiometabolic capability across a growing national footprint, which serves sponsors running multi-site cardiometabolic programs. Amavita concentrates all cardiovascular capability at one Miami address: one PI team, one set of cardiovascular SOPs, one BD owner (Nereisy Alonso, COO), and an enrollment funnel fed by an active cardiology practice.
For a sponsor whose program is multi-site by design, a network with cardiometabolic depth is a logical choice. For a sponsor that wants one South Florida site to deliver a cardiovascular cohort with TAVR-pioneer PI leadership, an on-site ASC, cardiac PET and radiopharmaceutical trial capability, and an anonymized 41-day contract-to-first-patient-in metric, the specialist model is the sharper instrument.
The two are not mutually exclusive. Sponsors regularly pair a lead specialist site in South Florida with network sites covering other regions - depth where it counts, breadth where it is needed.
Side-by-side: operating model
Educational summary. We describe the typical multi-site research network model and do not make claims about any specific institution's current operations.
| Dimension | Amavita Research | Headlands (typical) |
|---|---|---|
| Site type | Single dedicated cardiovascular site (Miami); PET imaging trial partner across therapeutic areas | Site network, HQ West Palm Beach, FL |
| Cardiovascular focus depth | Miami site 100% cardiovascular; PET imaging partnerships in oncology and neurology | Cardiometabolic emphasis across network sites |
| Senior PI profile | TAVR pioneer Dr. William W. O'Neill; National PI on Edwards PARTNER, Protect II, Protect IV | Network PI roster with cardiometabolic experience |
| Interventional procedures | On-site cardiovascular ASC (Advanced Cardiovascular of Miami) | Varies by site |
| BD contact model | Single owner: Nereisy Alonso, COO | Central network operations |
| Startup speed | 41-day contract-to-first-patient-in (anonymized program metric) | Network-standardized activation |
| Best fit | Single-site cardiovascular depth in South Florida | Multi-site cardiometabolic programs |
Frequently asked questions
Headlands is headquartered in Florida too - why compare?
Because sponsors evaluating Florida cardiovascular sites encounter both models: a West Palm Beach-headquartered network and an independent Miami specialist. The comparison is about operating model, not geography.
When does Headlands' network model win?
When the cardiometabolic program is multi-site by design and benefits from network-standardized operations across several regions.
What is Amavita's edge as a single site?
Concentration: a TAVR-pioneer PI, an on-site cardiovascular ASC, cardiac PET and radiopharmaceutical capability, and every operational dollar spent on cardiovascular research at one address.
Can the two models combine in one program?
Yes. A lead specialist site in South Florida plus network sites elsewhere is a standard sponsor playbook for cardiovascular programs.
Next step
Schedule a 20-minute capabilities call
One contact. Same-business-day response. Feasibility, budget, contracts, and monitor access all from a single owner.
For a comprehensive sponsor decision framework, read our 2026 site selection guide.
Other comparisons
- Amavita vs. Baptist Health
- Amavita vs. University of Miami
- Amavita vs. Flourish Research
- Amavita vs. Academic Medical Center
- Amavita vs. MCRC
- Amavita vs. SFCRI
- Amavita vs. Altior
- Amavita vs. Multi-Site Network
- Amavita vs. Hospital-Based Research
- Amavita vs. Academic Medical Center (general)
- Amavita vs. Mount Sinai
- Amavita vs. Cleveland Clinic Florida
- Amavita vs. Memorial Cardiac & Vascular
- Amavita vs. Velocity
- Amavita vs. Elligo
- Amavita vs. CIRA